^
    Back
    Association details:
    Biomarker:EGFR overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Portrazza (necitumumab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

    Excerpt:
    ...IHC H-score criteria assesses participants with a low EGFR expression defined by a H-score cutoff value of < 200 and participants with a high EGFR expression defined by a H-score of cutoff value of >=200....
    Trial ID:
    INSPIRE
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Palliat Med
    Title:

    Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials

    Published date:
    09/15/2020
    Excerpt:
    With a longer PFS and a higher DCR, NC treatment seemed to be more suitable for treating stage IV NSCLC as first-line therapy, especially for those with high EGFR expression, but its AEs could not be ignored.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.21037/apm-19-365